Innovative drug sector short-term surge, Taiji Group hits limit-up.

The innovative drug sector saw a short-term surge: Taiji Group hit the daily limit, and Yahuang Pharmaceutical, Saisheng Pharmaceutical, Shanghai RAAS, Medicilon, and Yuekang Pharmaceutical followed suit. Regarding related ETFs, the Innovation Drug ETF—Fuguo (159748) rose 1.05% with trading volume of 26.3652 million yuan, while the STAR Innovation Drug ETF—E Fund (589120) rose 1.42% with trading volume of 30.6628 million yuan. In terms of news flow, data from PharmaCube shows that in the first half of 2026, the value of China’s innovative drug BD overseas transactions totaled $99.7 billion, about 2 times that of 2024 and 73% of that in 2025.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned